Post-Marketing Pooled Safety Analysis for CT-P13 Treatment of Patients with Immune-Mediated Inflammatory Diseases in Observational Cohort Studies.

Sang Joon Lee KyungMin BaekSujin LeeYoon Jee Lee Jeong Eun ParkSeul Gi Lee

Published in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2021)

The CT-P13 safety profile appears consistent with previous studies for CT-P13 and reference infliximab, supporting the favourable risk/benefit balance for CT-P13 treatment.

Keyphrases

image quality
dual energy
computed tomography
contrast enhanced
positron emission tomography
magnetic resonance imaging
clinical trial
open label